You can talk to the chatbot like it's a friendly acquaintance, and it'll help you get a lot done. Amanda Smith is a freelance journalist and writer. She reports on culture, society, human interest and ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Abbott Laboratories (NYSE:ABT) agreed to acquire Exact ...

Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The US equity ...

The latest announcement is out from Exact Sciences ( (EXAS)). On November 19, 2025, Exact Sciences Corporation agreed to be acquired by Abbott Laboratories through a merger in which Exact will become ...

Madison leaders and economists are still working to predict all of the major changes that could take place with the sale of local cancer diagnostics company Exact Sciences to Illinois-based Abbott ...

Abstract: Background: In this study, we examined the effectiveness of three instruction-production arrangements: instruction-problem solving (I-PS), problem solving-instruction (PS-I), and problem ...

Shares of Exact Sciences (EXAS) continued to rise in the premarket on Thursday, adding ~18% after the cancer test maker agreed to be acquired by Abbott Laboratories (ABT) in an all-cash deal worth ...

Investing.com -- Exact Sciences (NASDAQ:EXAS) stock soared 17% Thursday, building on Wednesday’s 24% surge after Abbott (NYSE:ABT) announced plans to acquire the cancer diagnostics company in a deal ...

The cancer diagnostics specialist might, just might, be on the verge of selling itself. The apparent would-be buyer is a top name in the U.S. pharmaceutical industry. A strategic investor is ...

The rumors are now a reality. Abbott Laboratories is acquiring Exact Sciences for $21 billion, marking what could be the biggest medtech deal of 2025. The deal’s announcement comes less than 24 hours ...

Bloomberg reports today that Abbott (NYSE: ABT) + is close to a deal to acquire diagnostics developer Exact Sciences (Nasdaq:EXAS). The report cites people familiar with the matter. They reportedly ...

Bloomer announced, "We are raising total full year revenue to between $3.22 billion and $3.235 billion, an increase of $78 million at midpoint. This includes screening revenue between $2.51 billion ...